SpringWorks Therapeutics (SpringWorks Therapeutics) Total Inventories : $5.22 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics Total Inventories?

SpringWorks Therapeutics's total inventories for the quarter that ended in Mar. 2024 was $5.22 Mil. SpringWorks Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $4.16 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. SpringWorks Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $4.88.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. SpringWorks Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 315.77.

Inventory Turnover measures how fast the company turns over its inventory within a year. SpringWorks Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.29.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. SpringWorks Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.20.

SpringWorks Therapeutics Total Inventories Historical Data

The historical data trend for SpringWorks Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpringWorks Therapeutics Total Inventories Chart

SpringWorks Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

3.10

SpringWorks Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															-	-	-	3.10	5.22

SpringWorks Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

SpringWorks Therapeutics (NAS:SWTX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

SpringWorks Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(436.583	+	0.75 * 15.529	+	0.5 * 5.216	-	89.392
-	0	-	0)	/	74.0612
=	4.88

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

SpringWorks Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	4.1595	/	1.202	*	365 / 4
	=	315.77

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

SpringWorks Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	1.202	/	4.1595
	=	0.29

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

SpringWorks Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	4.1595	/	21.006
	=	0.20

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

SpringWorks Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Washington Boulevard, Stamford, CT, USA, 06902

Website

https://www.springworkstx.com

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Executives

Tai-an Lin	officer: Chief Scientific Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz	director, 10 percent owner	C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl	officer: Chief People Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy	officer: Chief Medical Officer	368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam	director, officer: Chief Executive Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith	officer: See Remarks	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess	officer: Head of Research & Development	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto	director, 10 percent owner	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar	officer: Chief Commercial Officer	C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris	officer: Chief Business Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902